NEW YORK, Feb. 6 (GenomeWeb News) - Lakeland Regional Cancer Center has licensed the Rosetta Resolver software system to investigate the clinical value of microarrays for assisting in cancer staging, the licensing partners said today.
The Florida-based center will use the technology for investigating the clinical value of oligonucleotide microarrays, according to a statement.
No further details were released.